【Scinopharm】February 2026 Revenue Reaches NT$207 Million (YoY +26.3%)
Scinopharm (1789) announced its February 2026 monthly revenue of NT$207 million, a significant year-on-year increase of 26.3%. As a globally important active pharmaceutical ingredient (API) supplier, this revenue growth reflects the stable increase in customer orders in high-barrier fields such as cancer drugs.
📋 Article Processing Timeline
- 📰 Published: February 1, 2026 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (1559h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:18 (16h 18m after Collected)
Company Code: 1789
Company Name: Scinopharm
Industry: Biotechnology and Medical Industry
Data Month: 2026-02
Current Month Revenue: 207,454 thousand NTD (NT$207 million)
Year-on-year Change from Same Month Last Year: +26.3%
Company Name: Scinopharm
Industry: Biotechnology and Medical Industry
Data Month: 2026-02
Current Month Revenue: 207,454 thousand NTD (NT$207 million)
Year-on-year Change from Same Month Last Year: +26.3%